The Denodo Platform enabled the real-time integration of myriad heterogeneous, distributed, structured, and semi-structured data sources across Abbvie’s holdings, regardless of whether they were in the process of being acquired.
Abbvie is an American publicly traded biopharmaceutical company founded in 2013 that focuses on delivering transformational medicines and products in several key therapeutic areas such as immunology, oncology, neuroscience, eye care, virology, and women’s health. Since their launch they have invested ~$50 billion in research to discover, develop and deliver new medicines. In 2022, Abbvie has approximately 50,000 employees and a revenue of $57.8 billion.
Abbvie, which produces a wide range of healthcare products, is focused on people. But a near-constant stream of mergers and acquisitions was preventing the company from keeping an accurate, up-to-the-minute list of all current employees. The Denodo Platform changed that.
Keeping the Data Together
Abbvie's main challenge was that a significant number of terminated employees and contingent workers were still listed on a number of Active Directory (AD) databases, enabling them to access confidential information or even use their badges to access restricted areas. Not only did this present a security risk, but if the names of the terminated employees were not removed from the AD systems within 30 days, Abbvie would fall out of compliance with SOX regulations, and risk having to pay significant penalties.
The Denodo Platform enabled the real-time integration of myriad heterogeneous, distributed, structured, and semi-structured data sources across Abbvie's holdings, regardless of where they were in the M&A process. The Denodo Platform enabled Abbvie to quickly integrate and manage the critical data that was relevant to its business operations.
- Website: www.abbvie.com
- Industry: Healthcare
- Location: USA
- Solution: Data Governance
- Product: Denodo Platform, On Premise
At a glance
Abbvie seamlessly integrated data across multiple heterogeneous sources.
Abbvie developed a more comprehensive drug development process.
Abbvie kept better track of current employees for SOX compliance.
The Denodo Platform eliminated the risk of IP theft and non-compliance.